The principles may be used to establish bioequivalence in applications for generic medicinal products, extensions of innovator products, variations that require bioequivalence testing, and between early clinical trial products and to-be-marketed products. II. Summary Requirements
If bioequivalence studies cannot be performed, pharmacodynamic or clinical studies should be carried out to evaluate therapeutic equivalence according to the studies for oral immediate release products and enteric-coated products. IV. Dissolution tests
A reference product whose content or potency is as close as possible to the labelled claim should be used. Furthermore, it is preferable that the difference between the content or potency of the test product and that of the reference product be within 5% of the labelled claim. II. Bioequivalence studies 1. Test methods
Assessment of bioequivalence If blood is the sampled body fluid, AUCt and Cmax should be used as the parameters for evaluation of bioequivalence in a single dose study, and AUCτ and Cmax should be used in a multiple dose study. The measured value should be used for Cmax, and the value calculated by the trapezoidal integration for AUC.